LOGIN  |  REGISTER
C4 Therapeutics
Assertio

iRhythm Technologies to Participate in Upcoming Investor Conferences

August 20, 2025 | Last Trade: US$178.28 1.72 0.97

SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences.

  • Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time)
  • Morgan Stanley Global Healthcare Conference 2025 on Tuesday, September 9, 2025, at 2:35 p.m. Eastern Time (11:35 a.m. Pacific Time)
  • Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025, at 12:50 p.m. Eastern Time (9:50 a.m. Pacific Time)

Interested parties may access live and archived webcasts of the presentations on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. For additional information about iRhythm, please visit its corporate website at irhythmtech.com.

Investor Contact
Stephanie Zhadkevich
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Kassandra Perry
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page